liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up: Results of a randomized controlled trial (SCHEDULE)
National Hospital Norway, Norway.
National Hospital Norway, Norway.
Sahlgrens University Hospital, Sweden.
Rigshosp, Denmark.
Visa övriga samt affilieringar
2017 (Engelska)Ingår i: Clinical Transplantation, ISSN 0902-0063, E-ISSN 1399-0012, Vol. 31, nr 9, artikel-id e13038Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

The Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance (SCHEDULE) trial was a 12month, randomized, open-label, parallel-group trial that compared everolimus (EVR; n=56) to conventional CsA (n=59) immunosuppression. Previously, we reported that EVR outperformed CsA in improving renal function and coronary artery vasculopathy, despite a higher rejection rate with EVR. This study aimed to compare the effects of these treatments on quality of life (QoL). Within five post-operative days, patients (mean age 50 +/- 13years, 27% women) were randomized to EVR or a standard CsA dosage (CsA group). This study assessed quality of life (QoL), based on the Short Form-36, EuroQol-5D, and Beck Depression Inventory (BDI). Assessments were performed pre-HTx and 12 and 36months post-HTx. At 12 and 36months, the groups showed similar improvements in Short Form-36 measures (at pre-HTx, 12 and 36months the values were as follows: Physical component summary: EVR: 31.5 +/- 110.9, 49.1 +/- 9.7, and 47.9 +/- 10.6; Pamp;lt;.01; CsA: 32.5 +/- 8.2, 48.4 +/- 8.5, and 46.5 +/- 11.5; Pamp;lt;.01; mental component summary: EVR: 46.0 +/- 12.0, 51.7 +/- 11.9, and 52.1 +/- 13.0; Pamp;lt;.01; CsA: 38.2 +/- 12.5, 53.4 +/- 7.1, and 54.3 +/- 13.0; Pamp;lt;.01); similar decrease in mean BDI (EVR: 10.9 +/- 10.2, 5.4 +/- 4.7, and 8.1 +/- 9.0; Pamp;lt;.01; CsA: 11.8 +/- 7.1, 6.3 +/- 5.4, and 6.2 +/- 6.5; Pamp;lt;.01); and similar Euro Qol-improvements. Thus, in this small-sized study, EVR-based and conventional CsA immunosuppressive strategies produced similar QoL improvements.

Ort, förlag, år, upplaga, sidor
WILEY , 2017. Vol. 31, nr 9, artikel-id e13038
Nyckelord [en]
heart transplantation; immunosuppression; quality of life
Nationell ämneskategori
Kirurgi
Identifikatorer
URN: urn:nbn:se:liu:diva-141127DOI: 10.1111/ctr.13038ISI: 000408913700009PubMedID: 28640529OAI: oai:DiVA.org:liu-141127DiVA, id: diva2:1144755
Tillgänglig från: 2017-09-27 Skapad: 2017-09-27 Senast uppdaterad: 2017-09-27

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Sök vidare i DiVA

Av författaren/redaktören
Jansson, Kjell
Av organisationen
Avdelningen för kardiovaskulär medicinHälsouniversitetetKardiologiska kliniken US
I samma tidskrift
Clinical Transplantation
Kirurgi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 45 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf